These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10811451)

  • 21. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody.
    Kaminski MS; Zasadny KR; Francis IR; Milik AW; Ross CW; Moon SD; Crawford SM; Burgess JM; Petry NA; Butchko GM
    N Engl J Med; 1993 Aug; 329(7):459-65. PubMed ID: 7687326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD22-directed monoclonal antibody therapy for lymphoma.
    Siegel AB; Goldenberg DM; Cesano A; Coleman M; Leonard JP
    Semin Oncol; 2003 Aug; 30(4):457-64. PubMed ID: 12939714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study.
    Sausville EA; Headlee D; Stetler-Stevenson M; Jaffe ES; Solomon D; Figg WD; Herdt J; Kopp WC; Rager H; Steinberg SM
    Blood; 1995 Jun; 85(12):3457-65. PubMed ID: 7780133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
    Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
    Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody.
    Mattes MJ; Shih LB; Govindan SV; Sharkey RM; Ong GL; Xuan H; Goldenberg DM
    Int J Cancer; 1997 May; 71(3):429-35. PubMed ID: 9139880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody targeted therapeutics for lymphoma: new focus on the CD22 antigen and RNA.
    Newton DL; Ryback SM
    Expert Opin Biol Ther; 2001 Nov; 1(6):995-1003. PubMed ID: 11728231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
    Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
    Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody.
    Goldenberg DM; Horowitz JA; Sharkey RM; Hall TC; Murthy S; Goldenberg H; Lee RE; Stein R; Siegel JA; Izon DO
    J Clin Oncol; 1991 Apr; 9(4):548-64. PubMed ID: 2066752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
    Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
    Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL; Stone MJ; Cunningham D; Fay J; Newman J; Collins R; May R; McCarthy M; Richardson J; Ghetie V
    Blood; 1993 Nov; 82(9):2624-33. PubMed ID: 8219217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
    Morschhauser F; Kraeber-Bodéré F; Wegener WA; Harousseau JL; Petillon MO; Huglo D; Trümper LH; Meller J; Pfreundschuh M; Kirsch CM; Naumann R; Kropp J; Horne H; Teoh N; Le Gouill S; Bodet-Milin C; Chatal JF; Goldenberg DM
    J Clin Oncol; 2010 Aug; 28(23):3709-16. PubMed ID: 20625137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab).
    Leonard JP; Link BK
    Semin Oncol; 2002 Feb; 29(1 Suppl 2):81-6. PubMed ID: 11842393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma.
    Vose JM; Bierman PJ; Enke C; Hankins J; Bociek G; Lynch JC; Armitage JO
    J Clin Oncol; 2005 Jan; 23(3):461-7. PubMed ID: 15534357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2.
    Stein R; Belisle E; Hansen HJ; Goldenberg DM
    Cancer Immunol Immunother; 1993 Oct; 37(5):293-8. PubMed ID: 7691407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting human cancer xenografts with monoclonal antibodies labeled using radioiodinated, diethylenetriaminepentaacetic acid-appended peptides.
    Stein R; Govindan SV; Mattes MJ; Shih LB; Griffiths GL; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3079s-3087s. PubMed ID: 10541347
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
    Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR
    Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone.
    Illidge T; Honeychurch J; Vandersteen A; Cragg M
    Cancer Biother Radiopharm; 2000 Dec; 15(6):581-91. PubMed ID: 11190490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody.
    Press OW; Eary JF; Badger CC; Martin PJ; Appelbaum FR; Levy R; Miller R; Brown S; Nelp WB; Krohn KA
    J Clin Oncol; 1989 Aug; 7(8):1027-38. PubMed ID: 2666588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support.
    Press OW; Eary JF; Appelbaum FR; Martin PJ; Badger CC; Nelp WB; Glenn S; Butchko G; Fisher D; Porter B
    N Engl J Med; 1993 Oct; 329(17):1219-24. PubMed ID: 7692295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
    J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.